跳至主要内容
临床试验/NCT00079157
NCT00079157已完成1 期

Phase I Study Of Telomerase Peptide Vaccination For Patients With Advanced Breast Cancer

Abramson Cancer Center at Penn Medicine2 个研究点 分布在 1 个国家目标入组 28 人开始时间: 2004年2月最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
28
试验地点
2

研究概览

简要总结

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Giving a vaccine with Montanide ISA-51 and sargramostim may cause a stronger immune response and kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy when given together with Montanide ISA-51 and sargramostim in treating patients with stage IV breast cancer.

详细描述

OBJECTIVES:

Primary

  • Determine the safety of telomerase: 540-548 peptide vaccine emulsified in Montanide ISA-51 and sargramostim (GM-CSF) in patients with HLA-A2-expressing stage IV breast cancer.

Secondary

  • Compare the generation of human telomerase reverse transcriptase (hTERT) peptide-specific vs cytomegalovirus peptide-specific cytotoxic T-lymphocyte (CTL) immunity in patients treated with this regimen.
  • Correlate the dose level of this regimen with the generation of hTERT-specific CTL immunity and the development of hTERT-specific autoimmunity in these patients.
  • Determine the tumor response in patients treated with this regimen.

研究设计

研究类型
Interventional
主要目的
Treatment

入排标准

年龄范围
18 Years 至 120 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验